Skip to main content
Log in

Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

In this study we investigated the pattern of T lymphocyte changes in 16 adult patients with acute myeloid leukaemia (8), non-Hodgkin's lymphoma (4) and Hodgkin's disease (4) treated with continuous infusion of recombinant interleukin-2 (rIL-2). Effects indicative of lymphocyte activation occurred even prior to any rIL-2 therapy in these patients, being most prominent in patients with active diseases. Following each course of cytokine therapy, there were further changes in these parameters. Significant rebound lymphocytoses occurred with a concomitant increase in the cytotoxic functions and induction of the cytotoxicity-linked cytoplasmic serine esterase. Hence, both the natural killer and lectin-dependent cellular cytotoxicity activities were up-regulated. There were also increases in the serum sIL-2 receptor, sCD4 and sCD8 levels. More CD3+ lymphocytes, especially cells bearing CD4, were also recruited to the pool of potential effector cells, as demonstrated by the greater proportion of cells expressing the cytoplasmic serine esterase.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bock SN, Lee RE, Fisher B, Rubin JT, Schwartzentruber DJ, Wei JP, Callender DPE, Yang JC, Lotze MT, Pizzo PA, Rosenberg SA (1990) A prospective randomised trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 8: 161–169

    Google Scholar 

  2. Burton JD, Weitz CH, Kay NE (1989) Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am J Hematol 30: 61–67

    Google Scholar 

  3. Gottlieb DJ, Prentice HG, Heslop HE, Bello-Fernandez C, Bianchi AC, Galazka AR, Brenner MK (1989) Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for haematological malignancy. Blood 74: 2335–2342

    Google Scholar 

  4. Hudig D, Redelman D, Minning LL (1984) The requirement for proteinase activity for human lymphocyte-mediated natural cytotoxicity (NK): evidence that the proteinase is serine dependent and has aromatic amino acid specificity of cleaveage. J Immunol 133: 2657–2654

    Google Scholar 

  5. Kriegler M, Perez C, De Fay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramification for the complex physiology of TNF. Cell 53: 45–53

    Google Scholar 

  6. Lim SH, Worman CP, Goldstone AH (1991) Production of tumourderived suppressor factors in patients with acute myeloid leukaemia. Leuk Res (in press)

  7. Munck Petersen C, Moller BK (1988) Immunological reactivity and bioactivity of tumour necrosis factor. Lancet 1: 934

    Google Scholar 

  8. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin-2-activated lymphocytes for leukaemia and lymphoma cells. Blood 68: 938–948

    Google Scholar 

  9. Pasternack MS, Verret CR, Liu MA, Eisen HN (1986) Serine esterase in cytolytic T lymphocytes. Nature 322: 740–743

    Google Scholar 

  10. Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA (1985) Lymphokine-activated killer (LAK) cell phenomenon: IV. Lysis by LAK cell clones of fresh human tumour cells from autologous and multiple allogeneic tumours. J Nat Cancer Inst 75: 67–75

    Google Scholar 

  11. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Leitman S, Leitman WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889–897

    Google Scholar 

  12. Rubin LA, Kurman CC, Fritz ME, Buddison WE, Boutin B, Yarchoan R, Nelson D (1985) Soluble interleukin-2 receptors are released from by activated human lymphoid cells in vitro. J Immunol 135: 3172–3177

    Google Scholar 

  13. Rubin LA, Jay G, Nelson DL (1986) The released interleukin-2 receptor binds interleukin-2 efficiency. J Immunol 137: 3841–3844

    Google Scholar 

  14. Simon MM, Simon HG, Fruth U, Epplen J, Muller-Hermelink HK, Kramer MD (1987) Cloned cytolytic T-effector cells and their malignant variants produce an extracellular matrix degrading trypsin-like serine proteinase. Immunology 60: 219–230

    Google Scholar 

  15. Tomkinson B, Brown MC, Ip SH, Carrabis S, Sullivan JL (1989) Soluble CD 8 during T cell activation. J Immunol 142: 2230–2236

    Google Scholar 

  16. Wagner L, Goldstone AH, Worman CP (1989) Demonstration of the increase in serine esterase-positive T cells in hairy-cell leukaemia undergoing alpha interferon therapy. Leukemia 3: 373–379

    Google Scholar 

  17. West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905

    Google Scholar 

  18. Young LHY, Liu CC, Joag S, Rafii S, Young JDE (1990) How lymphocytes kill. Annu Rev Med 41: 45–54

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lim, S.H., Worman, C., Jewell, A. et al. Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias. Cancer Immunol Immunother 33, 133–137 (1991). https://doi.org/10.1007/BF01742542

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01742542

Key words

Navigation